Antiplatelet therapy in acute coronary syndromes

Current Cardiology Reports

Volumn 10, Issue 4, 2008, Pages 327-333

  Barker, Colin M ^a   Price, Matthew J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR AGONIST; PURINERGIC RECEPTOR STIMULATING AGENT; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN; ADENOSINE; ADENOSINE PHOSPHATE; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD VESSEL REACTIVITY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DISEASE COURSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY INTERVENTION; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MICROEMBOLISM; MONOTHERAPY; MORTALITY; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRURITUS; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THIOPHENES; TICLOPIDINE;

EID: 54449095851     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0052-y     Document Type: Review

References (49)

1. Frelinger AL, Furman MI, Linden MD, et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006, 113: 2888-2896.
2. Cairns JA, Gent M, Singer J, et al.: Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985, 313: 1369-1375.
3. Wallentin LC: Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991, 18: 1587-1593.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. The Antithrombotic Trialists' Collaboration [no authors listed]. BMJ 2002, 324: 71-86.
5. Berger JS, Stebbins A, Granger CB, et al.: Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008, 117: 192-199.
6. Aleil B, Ravanat C, Cazenave JP, et al.: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3: 85-92.
7. Foster CJ, Prosser DM, Agans JM, et al.: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001, 107: 1591-1598.
8. Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998, 339: 1665-1671.
9. Haushofer A, Halbmayer WM, Prachar H: Neutropenia with ticlopidine plus aspirin. Lancet 1997, 349: 474-475.
10. Campo G, Valgimigli M, Gemmati D, et al.: Poor responsiveness to clopidogrel: Drug-specific or class-Effect mechanism?: evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007, 50: 1132-1137.
11. von Tiehl KF, Price MJ, Valencia R, et al.: Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007, 50: 2039-2043.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49: 1505-1516.
13. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345: 494-502.
14. Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358: 527-533.
15. Sabatine MS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352: 1179-1189
16. Sabatine MS, Cannon C, Gibson CM, et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005, 294: 1224-1232.
17. Price MJ, Coleman JL, Steinhubl SR, et al.: Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006, 98: 681-684.
18. Serebruany VL, Steinhubl SR, Berger PB, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45: 246-251.
19. Hochholzer W, Trenk D, Frundi D, et al.: Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111: 2560-2564.
20. Cuisset T, Frere C, Quilici J, et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006, 4: 542-549.
21. Buonamici P, Marcucci R, Migliorini A, et al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49: 2312-2317.
22. Price MJ, Endemann S, Gallapudi RR, et al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008 Feb 10 (Epub ahead of print).
23. von Beckerath N, Taubert D, Pogatsa-Murray G, et al.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112: 2946-2950.
24. Angiolillo DJ, Shoemaker SB, Desai B, et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007, 115: 708-716.
25. Leong JY, Baker RA, Shah PJ, et al.: Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005, 80: 928-933.
26. Kapetanakis EI, Medlam DA, Boyce SW, et al.: Clopidogrel administration prior to coronary artery bypass grafting surgery: The cardiologist's panacea or the surgeon's headache? Eur Heart J 2005, 26: 576-583.
27. Reichert MG, Robinson AH, Travis JA, et al.: Effects of a waiting period after clopidogrel treatment before performing coronary artery bypass grafting. Pharmacotherapy 2008, 2: 151-156.
28. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [no authors listed]. J Am Coll Cardiol 2007, 50: 652-726.
29. Price MJ: Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol 2008 (in press).
30. Jernberg T, Payne CD, Winters KJ, et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27: 1166-1173.
31. Payne CD, Li YG, Small DS, et al.: Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007, 50: 555-562.
32. Wiviott SD, Trenk D, Frelinger AL, et al.: Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasurgrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007, 116: 2923-2932.
33. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357: 2001-2015.
34. Springthorpe B,TBailey A, Barton P, et al.: From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007, 17: 6013-6018.
35. Husted S, Emanuelsson H, Heptinstall S, et al.: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27: 1038-1047.
36. Storey RF, Husted S, Harrington RA, et al.: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Cardiol Coll 2007, 50: 1852-1856.
37. Cannon CP, Husted S, Harrington RA, et al.: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DIS-PERSE-2 Trial. J Am Cardiol Coll 2007, 50: 1844-1851.
38. Storey RF, Oldroyd KG, Wilcox RG: Open multicentre study of the P 2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001, 85: 401-407.
39. Steinhubl SR, Oh JJ, Oestreich JH, et al.: Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008, 121: 527-534.
40. Greenbaum AB, Grines CL, Bittl JA, et al.: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am J Cardiol 2006, 151: 689.e1-689.e10.
41. Nurden AT, Nurden P: Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003, 23: 158-159.
42. ShattDl SJ, Newman PJ: Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004, 104: 1606-1615.
43. Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002, 359: 189-198.
44. Newby LK, Ohman EM, Christenson RH, et al.: Benefit of glycoprotein IIb/ IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The PARAGON-B Troponin T Substudy. Circulation 2001, 103: 2891-2896.
45. Kastrati A, Mehilli J, Neumann FJ, et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 Randomized Trial. JAMA 2006, 295: 1531-1538.
46. Kastrati A, Mehilli J, Schühlen H, et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350: 232-238.
47. Stone GW, Ware JH, Bertrand ME: Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial. JAMA 2007, 298: 2497-2506.
48. Bolognese L, Falsini G, Liistro F, et al.: Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST trial. J Am Coll Cardiol 2006, 47: 522-528.
49. Rao SV, Jollis JG, Harrington RA, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004, 292: 1555-1562.